We are passionate about delivering on the promise of amniotic fluid as an unique source of treatments shaping the future of health. We will deliver new therapies to patients where there are currently few treatment options, such as serious COVID-19 lung disease and non-healing wounds, and provide innovative products for hair and skin care.
We are determined to deliver on our promise of using unique amniotic fluid stem cell therapy to shape the future of regenerative medicine and to provide new therapies for patients with few treatment options.
AMNICELL was founded by Dr. Bruce Young, whose extensive research in the biology of amniotic fluid enabled him to recognize the tremendous potential of amniotic fluid in regenerative medicine. The research conducted during the last 10 years proved that amniotic fluid from the mother at normal full term pregnancies contains millions of pluripotent cells, which can be safely collected, frozen and stored for later clinical use.
Our CEO Caroline Einaugler has a Law degree and Masters in Information and Library Science. In addition to her marketing experience she has a background in operations, information management, and information assurance with both medical and legal information. She has held several leadership roles in information management. She was previously the CIO at AMNICELL.
Members of the Board of Directors represent expertise in business, biomedical industry, science, law and medicine.
Our focus at AMNICELL is to build on the science and develop a successful company. We are initially addressing a significant unmet medical need, such as serious COVID-19 and other lung disease and chronic non-healing wounds. We have partnered with a world-renowned center for clinical processing of stem cells, and a globally recognized hospital wound center for the initial trials with our product for wound care. AMNICELL is developing hair and skin care products as cosmeceuticals as well.